Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Almonty Stock Faces Critical Market Test

Robert Sasse by Robert Sasse
November 11, 2025
in Analysis, Commodities, Nasdaq, Penny Stocks
0
Almonty Stock
0
SHARES
201
VIEWS
Share on FacebookShare on Twitter

Almonty Industries confronts a pivotal moment as 120-day lock-up restrictions from its July Nasdaq listing are set to expire, potentially flooding the market with additional shares. This comes amid contrasting signals from market analysts who have recently upgraded their outlook on the tungsten producer, creating a potentially volatile scenario for investors.

Lock-Up Expiration Creates Supply Pressure

Trading restrictions on various Almonty securities—including warrants, convertible bonds, and shares held by directors and management—expire today. These limitations were established on July 14, 2025, as part of the company’s successful $90 million Nasdaq Capital Market listing.

While Almonty shares gained 2.14% to reach $7.15 on November 10, they remain below recent peak levels. The stock’s performance this year has been remarkable, surging over 400% since January, driven primarily by tungsten prices reaching multi-year highs between $580 and $645 per metric ton.

Strong Profit Turnaround Despite Revenue Shortfall

Almonty’s third-quarter results, released November 3, revealed a dramatic financial turnaround. The company reported net earnings of $33.2 million (diluted EPS: $0.13), a substantial improvement from the $5.3 million loss recorded during the same period last year. This reversal was largely powered by a $34.5 million gain from the revaluation of warrant liabilities.

Revenue increased 28% to $8.7 million, though this figure fell short of FactSet’s $11.3 million estimate. The revenue growth was attributed to stronger tungsten pricing and consistent production output from the Panasqueira mine in Portugal.

The company’s liquidity position strengthened significantly, with cash reserves swelling to $111.6 million as of September 30, 2025, compared to just $7.8 million at the end of 2024.

Should investors sell immediately? Or is it worth buying Almonty?

Analyst Confidence Remains Strong

Despite the revenue disappointment, financial analysts have maintained bullish positions on Almonty. B. Riley Securities raised its price target from $7 to $10 while reaffirming its buy recommendation, citing growing confidence in the company’s strategic positioning ahead of the completion of its Sangdong mine in South Korea.

Diamond Equity Research set an even more optimistic target of C$11 per share, pointing to strengthened tungsten prices and reduced execution risk following the Nasdaq listing.

Geopolitical Tensions Enhance Tungsten’s Strategic Value

Almonty stands to benefit from escalating geopolitical tensions that have positioned tungsten as a critical strategic mineral. As a leading non-Chinese tungsten supplier, the company is well-placed to serve defense and high-technology supply chains.

Construction of the Sangdong mine—destined to become the largest tungsten operation in the Western world—is nearing completion. In October, Almonty expanded its portfolio with the $10 million acquisition of the Genting Browns Lake project in Montana, with U.S. production expected to commence in the second half of 2026.

Industry specialists anticipate structural support for tungsten prices in the $400-$450 per metric ton range, driven by constrained supply outside China and increasing defense sector demand.

Ad

Almonty Stock: Buy or Sell?! New Almonty Analysis from February 7 delivers the answer:

The latest Almonty figures speak for themselves: Urgent action needed for Almonty investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Almonty: Buy or sell? Read more here...

Tags: Almonty
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Graftech Stock
Commodities

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Next Post
Nestle Stock

Is Nestlé Stock Signaling a Sustained Recovery?

Healwell AI Stock

Healwell AI Shares Face Mounting Analyst Pessimism

Lynas Stock

Lynas Receives Dual Boost with Index Inclusion and License Progress

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com